Oregonin inhibits inflammation and protects against barrier disruption in intestinal epithelial cells.

CONCLUSION: The findings of this study suggest that oregonin is a potential candidate for treatment of IBD by preventing mucosal inflammation and barrier disruption. PMID: 29655054 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research